Slide 1: For personal use only
“Never has scale been more important for the success and growth of a global business!”
Slide 2: For personal use only
For personal use only
Slide 3: Agenda
QUORUM @] Yam WELCOME CHARIMAN’S REPORT (ij Ua RESULTS STRATEGY 18 @ (om NOTICE OF MEETING CONSIDERATION OF REPORTS @% [ay BUSINESS - RESOLUTIONS 1 - 6 CLOSE OF MEETING @@ step QUESTION TIME
Slide 4: Our Governance
OUR GOVERNANCE Ms Sheena Jack Associate Prof Rob Phillips Mr Christian Bernecker Mr Brett Crowley Non-executive Executive Non-executive Company Secretary CEOUscom CEOHCF Independent investor representative Mr Chao Xian (David) He Non-Executive Director China Medical Devices
Slide 5: Thank You
THANK YOU 2017 has been a year of results for Uscom as we continue to grow our business based on improving operational fundamentals, while consolidating our acquisitions and preparing 7 new products for market and new revenue streams for FY 2018 and beyond. The outstanding achievements of 2017 repre
Slide 6: Chairman's Report: Our Vision
e CHAIRMAN’S REPORT OUR VISION Uscom is an innovator in cardiovascular and pulmonary medical devices, developing new non-invasive technologies to address the challenges of global disease and health care. OUR DRIVE Uscom is driven by a commercial ambition to become a leader in the global healthcare b
Slide 7: For personal use only
For personal use only
Slide 8: For personal use only
For personal use only $4.0 $3.5 $3.0 • $2.5 • • $2.0 • $1.5 $1.0 $0.5 $0.0 2012 2013 2014 2015 2016 2017
Slide 9: Our Results: Total Cash Receipts
e OUR RESULTS @ TOTAL CASH RECEIPTS x & S we) z Q. vet 2013 2014 2015 2016 2017 $3,522,859 $2,935,683 2017 cash receipts increased by “| 20% to $3.5m, and at a CAGR of 36% over the last 4 years. SAUD $1,043,460 $1,209,796
Slide 10: Cash Consumption and After Tax Losses
e OUR RESULTS e CASH CONSUMPTION AND AFTER TAX LOSSES 12016 © 2017 Despite significant spend on product development, 1.92 1.80 finalisation of acquisitions and regulatory payments, 1.29 $M AUD cash consumption 0.99 decreased 30%, while loss after taxes decreased 6% in 2017. CASH CONSUMPTION LOSS AFT
Slide 11: For personal use only
For personal use only 18.0 16.1 16.0 14.0 12.4 12.0 10.0 8.0 6.0 5.0 5.2 5.2 4.1 4.0 2.0 0.0 2012 2013 2014 2015 2016 2017
Slide 12: Our Acquisitions: Invested in Technology
° OUR ACQUISITIONS INVESTED IN TECHNOLOGY Uscom has invested in technology with two corporate acquisitions * central blood pressure monitoring * pulmonary function monitoring We have * integrated the companies * Redesigned, optimised + rebranded the new devices * prepared the products for market Lau
Slide 13: For personal use only
For personal use only
Slide 14: Concept, Patent, Prototype, Establish QC
CONCEPT PATENT PROTOTYPE ESTABLISH QC
Slide 15: Validation, Testing, Design, Manufacture
VALIDATION TESTING DESIGN MANUFACTURE
Slide 16: ISO Approval, Regulatory, Marketing
ISO APPROVAL REGULATORY MARKETING
Slide 17: Finish: Revenue
FINISH REVENUE The process of turning IP into revenue is a long and expensive one, and while Uscom’s current accounts reflect revenue predominantly from the USCOM 1A, the BP+ and SpiroSonic devices have been prepared for global sales. This investment represents significant value for Uscom shareholde
Slide 18: Range
RANGE The USCOM 1A is a non-invasive advanced hemodynamic monitor that measures cardiovascular function using Doppler ultrasound to detect abnormalities and guide treatment. The USCOM 1A has major applications in Paediatrics, Emergency, Intensive Care and Anaesthesia. rit 08 “76 80 NISMS The BP+ mea
Slide 19: For personal use only
For personal use only
Slide 20: For personal use only
For personal use only • • • • • • •
Slide 21: Practice
PRACTICE —— Rhythm Strip Data [ onde J coves J “ Teemestanee | | | — ] Uscom BP+ uses patent protected | a Sia suprasystolic oscillometry to measure blood PEIN A ce ||emone tna pressure at the heart rather than at the arm, % 7 ~ © * mt as normal subsystolic blood pressure ee oe sa a Be ken tpmnniman
Slide 22: Science
SCIENCE Uscom BP+ at MONS University Belgium Uscom devices are based on precision science, and part of the development of Uscom products is the rigorous testing required to support their release.
Slide 23: Lung Function for Every Breath You Take
LUNG FUNCTION . FOR EVERY BREATH YOU TAKE SpiroSonic)))
Slide 24: For personal use only
For personal use only • • • • • • • •
Slide 25: Our Science
e OUR SCIENCE =) Research Publications Repository The feasibility of transcutaneous continuous wave Doppler ultrasound monitoring of cardiac output: Ultrasonic Cardiac Output Monitor (USCOM) Australian Government IP Australia European O}}} Patent Office Patents and publications prove the value of Us
Slide 26: Regulation
e REGULATION Regulatory approval is required for device sales into China (CFDA), Europe (CE), FDA (USA) and Australia (TGA). Uscom has a number of pending approvals in various jurisdictions over the next 12 mths which will allow sales into new markets USCOM 1A —CFDA, CE, FDA, TGA BP+— CFDA (submissi
Slide 27: For personal use only
For personal use only • • • • • • • •
Slide 28: Growth China
e GROWTH CHINA STATE FUNDED GROWTH 1.38B population in:31 provinces 20% PA China health growth UCM CEO on NSW Govt China Advisory 10 year history + China Govt partners CFDA BP+ and SpiroSonic initiated China revenue targets $20M Yo HEALTH SPEND m China /USA 20 18 12 12 5.8 5.5 GROWTH GDP SPEND GDP G
Slide 29: Growth Sales
e GROWTH SALES @ GROWTH IN DISTRIBUTION AGREEMENTS Damien Linnett Global Sales Manager Appointed 2017 Bea Onal Marketing Coordinator Appointed 2017 Denise Pater 43 50 Global Distribution 36 Manager 23 a 2013 2014 2015 2016 2017 2018* Bev Jacobson Clinical Relations mROW China Manager
Slide 30: Why Now
WHY NOW After 5 years of investment Uscom is preparing for growth in 2018 founded on marketing of our 7 new products + New products —1 to 8 (+700%) * New distribution — 53 to 75 (+32%) * New regulatory approvals (CE, FDA and CFDA) * More revenue — $3.5M to $10M, 20M, 50M + Incremental growth — strat
Slide 31: Uscom
~~ a —_ Uscom “Uscom has acquired global assets to ensure reliable revenue growth over the next decade. Our strategy is to efficiently deliver the devices we have developed into global markets, and grow shareholder value.”
Slide 32: For personal use only
For personal use only